Share：
Share this content in WeChat
X
[Chinese][PDF]4443
• Clinical Article •
A Meta-analysis of myocardial tissue characteristics in patients with pulmonary hypertention evaluated by MR T1 mapping
YAN Chunlong  JIA Siqi  JIN Yuhua  QI Xianlong  SUN Yanqiu 

Cite this article as: YAN C L, JIA S Q, JIN Y H, et al. A Meta-analysis of myocardial tissue characteristics in patients with pulmonary hypertention evaluated by MR T1 mapping[J]. Chin J Magn Reson Imaging, 2023, 14(11): 38-41, 96. DOI:10.12015/issn.1674-8034.2023.11.007.


[Abstract] Objective To evaluate the diagnostic value of quantitative T1 mapping in cardiac magnetic resonance imaging for myocardial tissue characteristics in patients with pulmonary hypertention (PH) by Meta-analysis.Materials and Methods Relevant literatures were retrieved from Pubmed, Web of Science, the Cochrane Library, CNKI, Wanfang Database and VIP Database from the establishment of the database to December 31, 2022. Two researchers independently screened literatures, extracted data and evaluated the quality of the included literatures according to the inclusion and exclusion criteria. Meta-analysis was performed using Revman 5.4 software.Results A total of 8 literatures were included, including 613 PH patients and 150 healthy controls. The results of Meta-analysis showed that compared with the healthy control group, the initial T1 value of PH patients was significantly increased [odds ratio (OR)=123.22, 95% CI (112.92-133.52), P＜0.001]. Myocardial damage was obvious in inferior right ventricle insertion point (IRVIP) in PH group [OR=-82.94, 95% CI (-92.43--73.45), P＜0.001].Conclusions MR T1 mapping technique can evaluate the myocardial tissue characteristics of PH patients noninvasculatively, which has high clinical application value. Close attention should be paid to the myocardium of IRVIP.
[Keywords] cardiac magnetic resonance；T1 mapping；pulmonary hypertention；Meta-analysis；magnetic resonance imaging

YAN Chunlong1, 2, 3   JIA Siqi4   JIN Yuhua4   QI Xianlong1*   SUN Yanqiu3*  

1 Department of Radiology, Jining No.1 People's Hospital, Jining 272000, China

2 Graduate School, Soochow University, Suzhou 215004, China

3 CT Room, Qinghai Provincial People's Hospital, Xining 810007, China

4 School of Clinical Medicine, Jining Medical University, Jining 272000, China

Corresponding author: QI X L, E-mail: qixianlong@126.com SUN Y Q, E-mail: syqldn@126.com

Conflicts of interest   None.

ACKNOWLEDGMENTS Qinghai Provincial Health Committee Guiding Program Project (No. 2020-wjzdx-04); Qinghai Provincial Department of Science and Technology Basic Research Project (No. 2021-ZJ-732); Qinghai Province "Kunlun Elite High-end Innovative and Entrepreneurial Talents" Program to Cultivate Leading Talents (Youth Talent Word 2021 No. 13); Key R&D Program of Jining (No. 2023YXNS103).
Received  2023-01-10
Accepted  2023-10-23
DOI: 10.12015/issn.1674-8034.2023.11.007
Cite this article as: YAN C L, JIA S Q, JIN Y H, et al. A Meta-analysis of myocardial tissue characteristics in patients with pulmonary hypertention evaluated by MR T1 mapping[J]. Chin J Magn Reson Imaging, 2023, 14(11): 38-41, 96. DOI:10.12015/issn.1674-8034.2023.11.007.

[1]
Pulmonary Embolism and Pulmonary Vascular Disease Group, Respiratory Branch of Chinese Medical Association, Pulmonary Embolism and Pulmonary Vascular Disease Working Committee, Respiratory Physician Branch of Chinese Medical Doctor Association, National Collaborative Group on Pulmonary Embolism and Pulmonary Vascular Disease Prevention, et al. Guidelines for diagnosis and treatment of pulmonary hypertension in China (2021 edition)[J]. Natl Med J China, 2021, 101(1): 11-51. DOI: 10.3760/cma.j.cn112137-20201008-02778.
[2]
RUOPP N F, COCKRILL B A. Diagnosis and treatment of pulmonary arterial hypertension: a review[J]. JAMA, 2022, 327(14): 1379-1391. DOI: 10.1001/jama.2022.4402.
[3]
NAEIJE R, RICHTER M J, RUBIN L J. The physiological basis of pulmonary arterial hypertension[J/OL]. Eur Respir J, 2022, 59(6): 2102334 [2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/34737219/. DOI: 10.1183/13993003.02334-2021.
[4]
LUNA-LÓPEZ R, RUIZ MARTÍN A, ESCRIBANO SUBÍAS P. Pulmonary arterial hypertension[J]. Med Clínica Engl Ed, 2022, 158(12): 622-629. DOI: 10.1016/j.medcle.2022.05.010.
[5]
VAZQUEZ Z G S, KLINGER J R. Guidelines for the treatment of pulmonary arterial hypertension[J]. Lung, 2020, 198(4): 581-596. DOI: 10.1007/s00408-020-00375-w.
[6]
ZHAO X D, LENG S, TAN R S, et al. Right ventricular energetic biomarkers from 4D Flow CMR are associated with exertional capacity in pulmonary arterial hypertension[J/OL]. J Cardiovasc Magn Reson, 2022, 24(1): 61 [2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/36451198/. DOI: 10.1186/s12968-022-00896-8.
[7]
SHAHIN Y, ALABED S, REHAN QUADERY S, et al. CMR measures of left atrial volume index and right ventricular function have prognostic value in chronic thromboembolic pulmonary hypertension[J/OL]. Front Med, 2022, 9: 840196 [2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/35360708/. DOI: 10.3389/fmed.2022.840196.
[8]
HAAF P, GARG P, MESSROGHLI D R, et al. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review[J/OL]. J Cardiovasc Magn Reson, 2016, 18(1): 89 [2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/27899132/. DOI: 10.1186/s12968-016-0308-4.
[9]
ALABED S, SAUNDERS L, GARG P, et al. Myocardial T1-mapping and extracellular volume in pulmonary arterial hypertension: a systematic review and meta-analysis[J/OL]. Magn Reson Imaging, 2021, 79: 66-75 [2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/33745961/. DOI: 10.1016/j.mri.2021.03.011.
[10]
WESSELS J N, DE MAN F S, VONK NOORDEGRAAF A. The use of magnetic resonance imaging in pulmonary hypertension: why are we still waiting?[J/OL]. Eur Respir Rev, 2020, 29(156): 200139 [2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/32620588/. DOI: 10.1183/16000617.0139-2020.
[11]
SUNTHANKAR S D, GEORGE-DURRETT K, CRUM K, et al. Comprehensive cardiac magnetic resonance T1, T2, and extracellular volume mapping to define Duchenne cardiomyopathy[J/OL]. J Cardiovasc Magn Reson, 2023, 25(1): 44 [2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/37517994/. DOI: 10.1186/s12968-023-00951-y.
[12]
SREE RAMAN K, SHAH R, STOKES M, et al. Left ventricular ischemia in pre-capillary pulmonary hypertension: a cardiovascular magnetic resonance study[J]. Cardiovasc Diagn Ther, 2020, 10(5): 1280-1292. DOI: 10.21037/cdt-20-698.
[13]
SAUNDERS L C, JOHNS C S, STEWART N J, et al. Diagnostic and prognostic significance of cardiovascular magnetic resonance native myocardial T1 mapping in patients with pulmonary hypertension[J/OL]. J Cardiovasc Magn Reson, 2018, 20(1): 78 [2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/30501639/. DOI: 10.1186/s12968-018-0501-8.
[14]
HOMSI R, LUETKENS J A, SKOWASCH D, et al. Left ventricular myocardial fibrosis, atrophy, and impaired contractility in patients with pulmonary arterial hypertension and a preserved left ventricular function: a cardiac magnetic resonance study[J]. J Thorac Imaging, 2017, 32(1): 36-42. DOI: 10.1097/RTI.0000000000000248.
[15]
ASANO R, OGO T, MORITA Y, et al. Prognostic value of right ventricular native T1 mapping in pulmonary arterial hypertension[J/OL]. PLoS One, 2021, 16(11): e0260456 [2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/34843578/. DOI: 10.1371/journal.pone.0260456.
[16]
REITER U, REITER G, KOVACS G, et al. Native myocardial T1 mapping in pulmonary hypertension: correlations with cardiac function and hemodynamics[J]. Eur Radiol, 2017, 27(1): 157-166. DOI: 10.1007/s00330-016-4360-0.
[17]
CHEN Y Y, YUN H, JIN H, et al. Association of native T1 times with biventricular function and hemodynamics in precapillary pulmonary hypertension[J]. Int J Cardiovasc Imaging, 2017, 33(8): 1179-1189. DOI: 10.1007/s10554-017-1095-1.
[18]
WANG Y, LIN L, CAO J, et al. The application value of cardiac magnetic resonance quantitative T 1 mapping technique for risk stratification in patients with pulmonary arterial hypertension[J]. Natl Med J China, 2022, 102(37): 2963-2968. DOI: 10.3760/cma.j.cn112137-20220405-00703.
[19]
DOU R Y, ZHANG H S, ZHANG N, et al. MRI late gadolinium enhancement and T1 mapping technique in evaluation of left ventricular remodeling in pulmonary arterial hypertension with congenital heart disease[J]. Chin J Med Imag, 2019, 27(8): 589-593. DOI: 10.3969/j.issn.1005-5185.2019.08.007.
[20]
RAJAGOPAL S, YU Y R A. The pathobiology of pulmonary arterial hypertension[J]. Cardiol Clin, 2022, 40(1): 1-12. DOI: 10.1016/j.ccl.2021.08.001.
[21]
CHEN C Y, HUNG C C, CHIANG C H, et al. Pulmonary arterial hypertension in the elderly population[J]. J Chin Med Assoc, 2022, 85(1): 18-23. DOI: 10.1097/JCMA.0000000000000658.
[22]
MARON B A, ABMAN S H, ELLIOTT C G, et al. Pulmonary arterial hypertension: diagnosis, treatment, and novel advances[J]. Am J Respir Crit Care Med, 2021, 203(12): 1472-1487. DOI: 10.1164/rccm.202012-4317SO.
[23]
COONS J C, POGUE K, KOLODZIEJ A R, et al. Pulmonary arterial hypertension: a pharmacotherapeutic update[J/OL]. Curr Cardiol Rep, 2019, 21(11): 141 [2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/31758342/. DOI: 10.1007/s11886-019-1235-4.
[24]
VAN DE VEERDONK M C, BOGAARD H J, VOELKEL N F. The right ventricle and pulmonary hypertension[J]. Heart Fail Rev, 2016, 21(3): 259-271. DOI: 10.1007/s10741-016-9526-y.
[25]
HANSMANN G, DIEKMANN F, CHOUVARINE P, et al. Full recovery of right ventricular systolic function in children undergoing bilateral lung transplantation for severe PAH[J]. J Heart Lung Transplant, 2022, 41(2): 187-198. DOI: 10.1016/j.healun.2021.10.014.
[26]
HEERDT P M, SINGH I, ELASSAL A, et al. Pressure-based estimation of right ventricular ejection fraction[J]. ESC Heart Fail, 2022, 9(2): 1436-1443. DOI: 10.1002/ehf2.13839.
[27]
GELZINIS T A. Pulmonary hypertension in 2021: part I-definition, classification, pathophysiology, and presentation[J]. J Cardiothorac Vasc Anesth, 2022, 36(6): 1552-1564. DOI: 10.1053/j.jvca.2021.06.036.
[28]
KRASUSKI R A. Pulmonary hypertension[J/OL]. Cardiol Clin, 2022, 40(1): xi-xii [2023-01-09]. https://www.sciencedirect.com/science/article/abs/pii/S0733865121000862?via%3Dihub. DOI: 10.1016/j.ccl.2021.09.002.
[29]
MOLES V M, GRAFTON G. Pulmonary hypertension in heart failure with preserved ejection fraction[J]. Cardiol Clin, 2022, 40(4): 533-540. DOI: 10.1016/j.ccl.2022.06.007.
[30]
CASSADY S J, RAMANI G V. Right heart failure in pulmonary hypertension[J]. Cardiol Clin, 2020, 38(2): 243-255. DOI: 10.1016/j.ccl.2020.02.001.
[31]
YANG F, REN W, WANG D, et al. The variation in the diastolic period with interventricular septal displacement and its relation to the right ventricular function in pulmonary hypertension: a preliminary cardiac magnetic resonance study[J/OL]. Diagnostics, 2022, 12(8): 1970 [2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/36010320/. DOI: 10.3390/diagnostics12081970.
[32]
CUTHBERTSON I, MORRELL N W, CARUSO P. BMPR2 mutation and metabolic reprogramming in pulmonary arterial hypertension[J]. Circ Res, 2023, 132(1): 109-126. DOI: 10.1161/CIRCRESAHA.122.321554.
[33]
PU H X, CUI B B, LIU J, et al. Characterization and clinical significance of biventricular mechanics in patients with systemic lupus erythematosus by 3T cardiovascular magnetic resonance tissue tracking[J]. Quant Imaging Med Surg, 2022, 12(2): 1079-1095. DOI: 10.21037/qims-21-520.
[34]
DIEKMANN J, KOENIG T, THACKERAY J T, et al. Cardiac fibroblast activation in patients early after acute myocardial infarction: integration with MR tissue characterization and subsequent functional outcome[J]. J Nucl Med, 2022, 63(9): 1415-1423. DOI: 10.2967/jnumed.121.263555.
[35]
MESSROGHLI D R, MOON J C, FERREIRA V M, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)[J/OL]. J Cardiovasc Magn Reson, 2017, 19(1): 75 [2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/28992817/. DOI: 10.1186/s12968-017-0389-8.
[36]
GUO J J, WANG L L, WANG J Q, et al. Prognostic value of hepatic native T1 and extracellular volume fraction in patients with pulmonary arterial hypertension[J/OL]. J Am Heart Assoc, 2022, 11(22): e026254 [2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/36346060/. DOI: 10.1161/JAHA.122.026254.

PREV Myocardial fibrosis by late gadolinium enhancement-cardiovascular magnetic resonance and adverse outcomes in patients with hypertrophic cardiomyopathy: A Meta-analysis
NEXT Value of T1WI enhanced radiomics model for predicting EGFR mutations in non-small cell lung cancer
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn